Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs

被引:5
|
作者
Rasmussen, Hans E. [1 ]
Ma, Rick [1 ]
Wang, Jessie J. [2 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
关键词
2-STAGE DESIGNS;
D O I
10.1002/pst.1911
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sample size reestimation in a crossover, bioequivalence study can be a useful adaptive design tool, particularly when the intrasubject variability of the drug formulation under investigation is not well understood. When sample size reestimation is done based on an interim estimate of the intrasubject variability and bioequivalence is tested using the pooled estimate of intrasubject variability, type 1 error inflation will occur. Type 1 error inflation is caused by the pooled estimate being a biased estimator of the intrasubject variability. The type 1 error inflation and bias of the pooled estimator of variability are well characterized in the setting of a two-arm, parallel study. The purpose of this work is to extend this characterization to the setting of a crossover, bioequivalence study with sample size reestimation and to propose an estimator of the intrasubject variability that will prevent type 1 error inflation.
引用
收藏
页码:96 / 105
页数:10
相关论文
共 50 条
  • [1] Optimal adaptive sequential designs for crossover bioequivalence studies
    Xu, Jialin
    Audet, Charles
    DiLiberti, Charles E.
    Hauck, Walter W.
    Montague, Timothy H.
    Parr, Alan F.
    Potvin, Diane
    Schuirmann, Donald J.
    [J]. PHARMACEUTICAL STATISTICS, 2016, 15 (01) : 15 - 27
  • [2] Sequential design approaches for bioequivalence studies with crossover designs
    Potvin, Diane
    DiLiberti, Charles E.
    Hauck, Walter W.
    Parr, Alan F.
    Schuirman, Donald J.
    Smith, Robert A.
    [J]. PHARMACEUTICAL STATISTICS, 2008, 7 (04) : 245 - 262
  • [3] Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence
    Maurer, Willi
    Jones, Byron
    Chen, Ying
    [J]. STATISTICS IN MEDICINE, 2018, 37 (10) : 1587 - 1607
  • [4] Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'
    Montague, Timothy H.
    Potvin, Diane
    DiLiberti, Charles E.
    Hauck, Walter W.
    Parr, Alan F.
    Schuirmann, Donald J.
    [J]. PHARMACEUTICAL STATISTICS, 2012, 11 (01) : 8 - 13
  • [5] Group sequential crossover trial designs with strong control of the familywise error rate
    Grayling, Michael J.
    Wason, James M. S.
    Mander, Adrian P.
    [J]. SEQUENTIAL ANALYSIS-DESIGN METHODS AND APPLICATIONS, 2018, 37 (02): : 174 - 203
  • [6] Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates
    Anders Fuglsang
    [J]. The AAPS Journal, 2013, 15 : 659 - 661
  • [7] Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates
    Fuglsang, Anders
    [J]. AAPS JOURNAL, 2013, 15 (03): : 659 - 661
  • [8] COMPARISON OF REPLICATE AND SIMPLE CROSSOVER DESIGNS IN BIOEQUIVALENCE STUDIES
    Roman, M.
    Ochoa, D.
    Belmonte, C.
    Vilchez, S.
    Valdez, S. E.
    Abad-Santos, F.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 30 - 31
  • [9] An iterative method to protect the type I error rate in bioequivalence studies under two-stage adaptive 2x2 crossover designs
    Molins, Eduard
    Labes, Detlew
    Schuetz, Helmut
    Cobo, Erik
    Ocana, Jordi
    [J]. BIOMETRICAL JOURNAL, 2021, 63 (01) : 122 - 133
  • [10] Sample size calculation for bioequivalence studies with high-order crossover designs
    Qu, RP
    Zheng, HJ
    [J]. CONTROLLED CLINICAL TRIALS, 2003, 24 (04): : 436 - 439